Review of delta‐8‐tetrahydrocannabinol (Δ8‐THC): Comparative pharmacology with Δ9‐THC
M Tagen, LE Klumpers - British journal of pharmacology, 2022 - Wiley Online Library
The use of the intoxicating cannabinoid delta‐8‐tetrahydrocannabinol (Δ8‐THC) has grown
rapidly over the last several years. There have been dozens of Δ8‐THC studies dating back …
rapidly over the last several years. There have been dozens of Δ8‐THC studies dating back …
[HTML][HTML] Neutral CB1 receptor antagonists as pharmacotherapies for substance use disorders: rationale, evidence, and challenge
O Soler-Cedeno, ZX Xi - Cells, 2022 - mdpi.com
Cannabinoid receptor 1 (CB1R) has been one of the major targets in medication
development for treating substance use disorders (SUDs). Early studies indicated that …
development for treating substance use disorders (SUDs). Early studies indicated that …
Oral efficacy of Δ (9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model
VA Mitchell, J Harley, SL Casey, AC Vaughan… - …, 2021 - Elsevier
The psychoactive and non-psychoactive constituents of cannabis, Δ9-tetrahydrocannabinol
(THC) and cannabidiol (CBD), have synergistic analgesic efficacy in animal models of …
(THC) and cannabidiol (CBD), have synergistic analgesic efficacy in animal models of …
Cannabinoid CB1 receptors are expressed in a subset of dopamine neurons and underlie cannabinoid-induced aversion, hypoactivity, and anxiolytic effects in mice
Cannabinoids modulate dopamine (DA) transmission and DA-related behavior, which has
been thought to be mediated initially by activation of cannabinoid CB1 receptors (CB1Rs) on …
been thought to be mediated initially by activation of cannabinoid CB1 receptors (CB1Rs) on …
Cannabinoid CB2 receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice
Cannabinoids produce a number of central nervous system effects via the CB 2 receptor (CB
2 R), including analgesia, antianxiety, anti-reward, hypoactivity and attenuation of opioid …
2 R), including analgesia, antianxiety, anti-reward, hypoactivity and attenuation of opioid …
Cannabis constituents for chronic neuropathic pain; reconciling the clinical and animal evidence
E Sokolaj, N Assareh, K Anderson… - Journal of …, 2023 - Wiley Online Library
Chronic neuropathic pain is a debilitating pain syndrome caused by damage to the nervous
system that is poorly served by current medications. Given these problems, clinical studies …
system that is poorly served by current medications. Given these problems, clinical studies …
[HTML][HTML] GPR55 is expressed in glutamate neurons and functionally modulates drug taking and seeking in rats and mice
Y He, H Shen, GH Bi, HY Zhang… - Translational …, 2024 - nature.com
G protein-coupled receptor 55 (GPR55) has been thought to be a putative cannabinoid
receptor. However, little is known about its functional role in cannabinoid action and …
receptor. However, little is known about its functional role in cannabinoid action and …
Beta-caryophyllene inhibits cocaine addiction-related behavior by activation of PPARα and PPARγ: repurposing a FDA-approved food additive for cocaine use …
Cocaine abuse continues to be a serious health problem worldwide. Despite intense
research, there is still no FDA-approved medication to treat cocaine use disorder (CUD). In …
research, there is still no FDA-approved medication to treat cocaine use disorder (CUD). In …
Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice
GC Glatfelter, JS Partilla, MH Baumann - Neuropsychopharmacology, 2022 - nature.com
Synthetic cannabinoid receptor agonists (SCRAs) are an evolving class of new psychoactive
substances found on recreational drug markets worldwide. The indole-containing …
substances found on recreational drug markets worldwide. The indole-containing …
[HTML][HTML] Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research
Abstract Cannabinoid CB1 receptors (CB1Rs) have been major targets in medication
development for the treatment of substance use disorders. However, clinical trials with …
development for the treatment of substance use disorders. However, clinical trials with …